Otsuka's Abilify Global Sales Reach ¥100 Billion
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Otsuka Holdings said its best selling antipsychotic Abilify (aripiprazole) global sales were ¥100.6 billion at the end of the second quarter, growing 2.4%